Internal Medicine
| 1 min read
| 3 min read
| 2 min read
Eli Lilly & Co. pilot study utilizes Optimata’s “virtual patient” technology to assist in the development of clinical trials for a novel anti-cancer cytotoxic compound.
| 2 min read
ProMetic Lifes Sciences Inc. and Goettingen, Germany-based Sartorius AG entered into a pair of collaborative agreements in the area of protein purification, one of which will create \"affinity composites\" using ProMetic’s Mimetic Ligand technology in conjunction with Sartorius’ membrane chromatography technology called Sartobind.
| 2 min read
Codexis Inc. announced the signing of a research agreement with Schering-Plough that will see the privately-held company develop novel synthetic processes for the pharma giant.
| 2 min read
| 3 min read
Biomedical imaging in playing an increasingly larger role in drug discovery. Ultrasonics, however, still brings to mind images of pregnant mothers and unborn babies. Toronto-based VisualSonics is hoping to change that impression. Recently, Executive Editor Randall C Willis spoke with VisualSonics President and CEO Tom Little.
| 2 min read
The cash keeps flowing for the dominant players in developing RNAi therapies, as evidenced recently by a multi-year strategic alliance between pharma giant GlaxoSmithKline and siRNA specialist Sirna Therapeutics Inc. that has the potential to pump more than $700 million into Sirna coffers.
| 1 min read
As mouse models of human disease become more important in drug discovery,
| 1 min read
Key to cell biology is the ability to introduce exogenous DNA into cells, but physicochemical methods such as transfection or electroporation often exhibit low efficiencies and can lead to cell damage.
